Olumiant

(baricitinib)
baricitinib 1 MG Oral Tablet [Olumiant]baricitinib 2 MG Oral Tablet [Olumiant]
View 1 more

Dosage & administration

Administration Instructions:

Recommended Dosage:

Rheumatoid Arthritis:


COVID-19:


Alopecia Areata:


Dosage Modifications in Patients with Renal or Hepatic Impairment, or Cytopenias


drug label

Olumiant prescribing information

samples

Request Olumiant samples

Online Sample Form
Learn More

prior authorization

Olumiant prior authorization resources

Most recent Olumiant prior authorization forms

View By Payer
Verified: Feb 07, 2024Kaiser Foundation Health Plan - Chronic High-Dose Opioid Therapy Prior Authorization Form Washington
Verified: Feb 01, 2024Highmark BCBS Northeastern NY - Medical Injectable Specialty Drug Prior Authorization Form
Verified: Feb 01, 2024Highmark BCBS Northeastern NY - Outpatient Chemotherapy Prior Authorization Form (Medical Benefit)
Verified: Feb 01, 2024Highmark BCBS Northeastern NY - Specialty Drug Prior Authorization Form
Verified: Feb 01, 2024Highmark BCBS Northeastern NY - Non-Formulary Drug Coverage Prior Authorization Form

Most recent state uniform prior authorization forms

Verified: Jan 28, 2024Oregon - Uniform Prior Authorization Form
Verified: Jan 28, 2024Colorado - Uniform Prior Authorization Form
Verified: Jan 28, 2024Michigan - Uniform Prior Authorization Form
Verified: Jan 28, 2024Hawaii - Uniform Prior Authorization Form
Verified: Jan 28, 2024Minnesota - Uniform Prior Authorization Form
Verified: Jan 28, 2024New Hampshire - Uniform Prior Authorization Form
Verified: Jan 28, 2024New Mexico - Uniform Prior Authorization Form
Verified: Jan 28, 2024Texas - Uniform Prior Authorization Form
Verified: Jan 28, 2024Louisiana - Uniform Prior Authorization Form
Verified: Jan 28, 2024Arizona - Uniform Prior Authorization Form
Verified: Jan 28, 2024Indiana - Uniform Prior Authorization Form
Verified: Jan 28, 2024Illinois - Uniform Prior Authorization Form
Complete Letter of Medical Necessity
Coverage Authorization Request
Coverage Authorization Appeals
Coverage Authorization Request - Editable Letter
Coverage Authorization Appeals - Editable Letter
Letter of Medical Necessity - Editable Letter
Learn More

Benefits investigation

Olumiant Together Enrollment Form: Dermatology
Olumiant Together Enrollment Form: Rheumatology
Learn More

pharmacy

Olumiant preferred pharmacy

Pharmacy List

financial assistance

Olumiant financial assistance options

Co-pay savings program

commercial only
Enroll in Patient Savings Program
Olumiant Together Enrollment Form: Dermatology
Olumiant Together Enrollment Form: Rheumatology
Learn More

Foundation programs

under insured
no insurance
goverment insurance
65+
Lilly Cares Foundation Eligibility Check
Lilly Cares Patient Assistance Program Application: Online
Lilly Cares Patient Assistance Program Application: English
Lilly Cares Patient Assistance Program Application: Spanish
Learn More

PubMed™ | Olumiant

Olumiant PubMed™ News

patient education

Olumiant patient education

To share resource; ask patient to:
1.Pull out phone
2.Open camera
3.Scan QR code with camera
4.Tap link

Patient toolkit

About Olumiant: Rheumatoid Arthritis
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
About Olumiant: Alopecia Areata
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
View How to Take Olumiant & Side Effects
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Learn More

Other resources

Olumiant Together App
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Learn More

people also ask

Olumiant FAQs

Is OLUMIANT safe to use during pregnancy?Based on animal studies, OLUMIANT may cause fetal harm during pregnancy. Available data from clinical trials and postmarketing case reports with OLUMIANT exposure in pregnancy are insufficient to inform a drug-associated risk for major birth defects, miscarriage, or other adverse maternal or fetal outcomes. There are no human data on chronic baricitinib exposure throughout pregnancy. Consider the risks and benefits with chronic use of OLUMIANT during pregnancy.
Can OLUMIANT be used during breastfeeding?No information is available on the presence of OLUMIANT in human milk, the effects of the drug on the breastfed infant, or the effects of the drug on milk production. Because of the potential for serious adverse reactions in nursing infants, advise women not to breastfeed during treatment with OLUMIANT and for 4 days after the last dose.
Is OLUMIANT safe for use in pediatric patients?The safety and effectiveness of OLUMIANT in pediatric patients have not been established.
Can OLUMIANT be used in geriatric patients?No overall differences in safety or effectiveness were observed between geriatric patients (65 years of age and older) and younger subjects in clinical trials. However, greater sensitivity of some older individuals cannot be ruled out. Care should be taken in dose selection and it may be useful to monitor renal function as geriatric patients are more likely to have decreased renal function.
Can OLUMIANT be used in patients with hepatic impairment?No dose adjustment is necessary in patients with mild or moderate hepatic impairment. OLUMIANT has not been studied in patients with rheumatoid arthritis or alopecia areata and severe hepatic impairment and is therefore not recommended. OLUMIANT should only be used in patients with COVID-19 and severe hepatic impairment if the potential benefit outweighs the potential risk.
Can OLUMIANT be used in patients with renal impairment?Renal function significantly affects baricitinib exposure. The recommended dosage of OLUMIANT in patients with moderate renal impairment (estimated glomerular filtration rate (GFR) between 30 and <60 mL/min/1.73 m2) should be reduced by half the recommended dose. OLUMIANT is not recommended for use in patients with rheumatoid arthritis or alopecia areata and severe renal impairment (estimated GFR of less than 30 mL/min/1.73 m2).
FAQ Data Source